Glutathione

FDA issued a June 7, 2019 alert after reports of adverse events in people receiving compounded intravenous glutathione. Its investigation found excessive bacterial endotoxin in ingredient samples. This is dated safety context, not a newly issued 2026 alert.

The ingredient at issue was marketed for dietary-supplement use, not sterile drugs. FDA says materials not intended for sterile injectable compounding can contain harmful impurities and contaminants. The findings concern the investigated products and do not prove that every glutathione product has the same contamination.

FDA emphasizes building quality into production rather than relying on testing alone. This safety alert is not evidence of an anti-aging, detoxification or wellness benefit. We do not give a regimen or direct readers to sellers.